Full-Time

Scientist

Confirmed live in the last 24 hours

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Compensation Overview

$95k - $105k/yr

+ Bonus + Equity Grant

Mid, Senior

North Bethesda, MD, USA

Relocation assistance is offered for roles if required.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Arcellx referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • BS or MS in the life sciences (e.g., biology, genetics, biochemistry, chemistry, chemical engineering, bioengineering) with 4-8 years post-degree lab experience or PhD in the life sciences with 0-3 years post-degree experience.
  • Must demonstrate mastery of molecular biology methods, including primer design, PCR, gel electrophoresis, expression construct design cloning and sequence analysis.
Responsibilities
  • Work with an interdisciplinary team of scientists to design, engineer and express recombinant proteins for use in the discovery and development of cancer therapies.
  • Design, construct and evaluate expression plasmids. Perform transfections, transductions, phage and yeast display enabled selections & screenings, binding kinetic assessments and flow cytometry as needed.
  • Develop new methods, technologies and processes when necessary for project.
  • Exercise significant technical discretion in the design, execution and interpretation of experiments.
  • Communicate progress and project recommendations to team members.
Desired Qualifications
  • Preferred skills include: methods for the characterization of recombinant protein quality and binding, protein display (phage, yeast and library preparation).
  • Preference for experience in drug development, immunology or protein engineering.

Arcellx develops immunotherapies aimed at transforming cell therapy for serious diseases. The company focuses on creating advanced treatments that utilize cell therapy techniques, targeting unmet medical needs. Its products are designed to be effective and safe, and the company collaborates with healthcare providers and research institutions to bring these therapies to patients. Arcellx generates revenue through partnerships, licensing agreements, and product sales after obtaining regulatory approval. What sets Arcellx apart from competitors is its commitment to addressing specific medical needs through proprietary immunotherapy products.

Company Size

51-200

Company Stage

IPO

Headquarters

Gaithersburg, Maryland

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.
  • Advancements in gene editing technologies can enhance Arcellx's cell therapy precision.
  • Increasing use of real-world evidence supports Arcellx's ongoing clinical studies.

What critics are saying

  • Competition from companies like Legend Biotech and Johnson & Johnson's Carvykti.
  • Potential delays in clinical trials due to unforeseen adverse events.
  • High cost of CAR-T therapy development impacts pricing and accessibility.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.
  • The ARC-SparX platform offers dosable and controllable CAR-T therapy options.
  • Anito-cel uses a novel D-Domain BCMA binder for enhanced cell killing efficiency.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

2%

2 year growth

1%
Business Wire
Mar 20th, 2025
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Arcellx appoints Andrew Galligan and Kristin Myers to its Board of Directors.

BioSpace
Feb 28th, 2025
Arcellx To Participate At The Td Cowen 45Th Annual Health Care Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET.A live webcast of this discussion will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.About Arcellx, Inc.Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible

Business Wire
May 9th, 2024
Kite And Arcellx Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Business Wire
May 9th, 2024
Arcellx And Kite Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Yahoo Finance
Mar 2nd, 2024
Earnings Update: Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Are Boosting Their Estimates

Arcellx, Inc. (NASDAQ:ACLX) just released its full-year report and things are looking bullish.